Literature DB >> 26787866

Diminished viral replication and compartmentalization of hepatitis C virus in hepatocellular carcinoma tissue.

Djamila Harouaka1, Ronald E Engle1, Kurt Wollenberg2, Giacomo Diaz3, Ashley B Tice1, Fausto Zamboni4, Sugantha Govindarajan5, Harvey Alter6, David E Kleiner7, Patrizia Farci8.   

Abstract

Analysis of hepatitis C virus (HCV) replication and quasispecies distribution within the tumor of patients with HCV-associated hepatocellular carcinoma (HCC) can provide insight into the role of HCV in hepatocarcinogenesis and, conversely, the effect of HCC on the HCV lifecycle. In a comprehensive study of serum and multiple liver specimens from patients with HCC who underwent liver transplantation, we found a sharp and significant decrease in HCV RNA in the tumor compared with surrounding nontumorous tissues, but found no differences in multiple areas of control non-HCC cirrhotic livers. Diminished HCV replication was not associated with changes in miR-122 expression. HCV genetic diversity was significantly higher in livers containing HCC compared with control non-HCC cirrhotic livers. Tracking of individual variants demonstrated changes in the viral population between tumorous and nontumorous areas, the extent of which correlated with the decline in HCV RNA, suggesting HCV compartmentalization within the tumor. In contrast, compartmentalization was not observed between nontumorous areas and serum, or in controls between different areas of the cirrhotic liver or between liver and serum. Our findings indicate that HCV replication within the tumor is restricted and compartmentalized, suggesting segregation of specific viral variants in malignant hepatocytes.

Entities:  

Keywords:  HCV RNA levels; HCV quasispecies; hepatitis C virus; hepatocellular carcinoma; liver

Mesh:

Substances:

Year:  2016        PMID: 26787866      PMCID: PMC4747736          DOI: 10.1073/pnas.1516879113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  54 in total

1.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

2.  Not so different after all: a comparison of methods for detecting amino acid sites under selection.

Authors:  Sergei L Kosakovsky Pond; Simon D W Frost
Journal:  Mol Biol Evol       Date:  2005-02-09       Impact factor: 16.240

3.  Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA.

Authors:  Catherine L Jopling; Minkyung Yi; Alissa M Lancaster; Stanley M Lemon; Peter Sarnow
Journal:  Science       Date:  2005-09-02       Impact factor: 47.728

4.  Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues.

Authors:  Y Murakami; T Yasuda; K Saigo; T Urashima; H Toyoda; T Okanoue; K Shimotohno
Journal:  Oncogene       Date:  2006-04-20       Impact factor: 9.867

5.  Relative quantification and mapping of hepatitis C virus by in situ hybridization and digital image analysis.

Authors:  J Gosálvez; E Rodríguez-Iñigo; J L Ramiro-Díaz; J Bartolomé; J F Tomás; H Oliva; V Carreño
Journal:  Hepatology       Date:  1998-05       Impact factor: 17.425

6.  Compartmentalization of hepatitis C virus quasispecies in blood mononuclear cells of patients with mixed cryoglobulinemic syndrome.

Authors:  Gianguglielmo Zehender; Chiara De Maddalena; Flavia Bernini; Erika Ebranati; Giuseppe Monti; Piero Pioltelli; Massimo Galli
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

7.  Downregulation of miR-122 in the rodent and human hepatocellular carcinomas.

Authors:  Huban Kutay; Shoumei Bai; Jharna Datta; Tasneem Motiwala; Igor Pogribny; Wendy Frankel; Samson T Jacob; Kalpana Ghoshal
Journal:  J Cell Biochem       Date:  2006-10-15       Impact factor: 4.429

8.  Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma.

Authors:  Laura Gramantieri; Manuela Ferracin; Francesca Fornari; Angelo Veronese; Silvia Sabbioni; Chang-Gong Liu; George A Calin; Catia Giovannini; Eros Ferrazzi; Gian Luca Grazi; Carlo M Croce; Luigi Bolondi; Massimo Negrini
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

9.  Development of a TaqMan assay for the six major genotypes of hepatitis C virus: comparison with commercial assays.

Authors:  Ronald E Engle; Rodney S Russell; Robert H Purcell; Jens Bukh
Journal:  J Med Virol       Date:  2008-01       Impact factor: 2.327

10.  Distinct hepatitis C virus core and F protein quasispecies in tumoral and nontumoral hepatocytes isolated via microdissection.

Authors:  Rodolphe Sobesky; Cyrille Feray; François Rimlinger; Nicolas Derian; Alexandre Dos Santos; Anne-Marie Roque-Afonso; Didier Samuel; Christian Bréchot; Valérie Thiers
Journal:  Hepatology       Date:  2007-12       Impact factor: 17.425

View more
  23 in total

1.  Molecular Signature and Mechanisms of Hepatitis D Virus-Associated Hepatocellular Carcinoma.

Authors:  Giacomo Diaz; Ronald E Engle; Ashley Tice; Marta Melis; Stephanie Montenegro; Jaime Rodriguez-Canales; Jeffrey Hanson; Michael R Emmert-Buck; Kevin W Bock; Ian N Moore; Fausto Zamboni; Sugantha Govindarajan; David E Kleiner; Patrizia Farci
Journal:  Mol Cancer Res       Date:  2018-06-01       Impact factor: 5.852

2.  Viral hepatitis: HCV compartmentalization in HCC: driver, passenger or both?

Authors:  Jacinta A Holmes; Raymond T Chung
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-03-23       Impact factor: 46.802

3.  Retinoic Acid-Inducible Gene I-Like Receptors Activate Snail To Limit RNA Viral Infections.

Authors:  Dhiviya Vedagiri; Divya Gupta; Anurag Mishra; Gayathri Krishna; Meenakshi Bhaskar; Vishal Sah; Anirban Basu; Debasis Nayak; Manjula Kalia; Mohanan Valiya Veettil; Krishnan Harinivas Harshan
Journal:  J Virol       Date:  2021-08-11       Impact factor: 5.103

4.  Chitinase 3-like 1 is a profibrogenic factor overexpressed in the aging liver and in patients with liver cirrhosis.

Authors:  Norihisa Nishimura; Davide De Battista; David R McGivern; Ronald E Engle; Ashley Tice; Rafaelle Fares-Gusmao; Juraj Kabat; Anna Pomerenke; Hanh Nguyen; Shinya Sato; Kevin W Bock; Ian N Moore; David E Kleiner; Fausto Zamboni; Harvey J Alter; Sugantha Govindarajan; Patrizia Farci
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-27       Impact factor: 11.205

5.  Multifaceted role of E-cadherin in hepatitis C virus infection and pathogenesis.

Authors:  Che C Colpitts; Joachim Lupberger; Thomas F Baumert
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-24       Impact factor: 12.779

6.  Exceptional Heterogeneity in Viral Evolutionary Dynamics Characterises Chronic Hepatitis C Virus Infection.

Authors:  Jayna Raghwani; Rebecca Rose; Isabelle Sheridan; Philippe Lemey; Marc A Suchard; Teresa Santantonio; Patrizia Farci; Paul Klenerman; Oliver G Pybus
Journal:  PLoS Pathog       Date:  2016-09-15       Impact factor: 6.823

7.  Phylogenetic Diversity in Core Region of Hepatitis C Virus Genotype 1a as a Factor Associated with Fibrosis Severity in HIV-1-Coinfected Patients.

Authors:  Micaela Parra; Natalia Laufer; Julieta M Manrique; Leandro R Jones; Jorge Quarleri
Journal:  Biomed Res Int       Date:  2017-11-12       Impact factor: 3.411

Review 8.  Hepatitis D Virus and Hepatocellular Carcinoma.

Authors:  Patrizia Farci; Grazia Anna Niro; Fausto Zamboni; Giacomo Diaz
Journal:  Viruses       Date:  2021-05-04       Impact factor: 5.048

9.  Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir.

Authors:  Ana I de Ávila; Isabel Gallego; Maria Eugenia Soria; Josep Gregori; Josep Quer; Juan Ignacio Esteban; Charles M Rice; Esteban Domingo; Celia Perales
Journal:  PLoS One       Date:  2016-10-18       Impact factor: 3.240

10.  Hepatitis C virus NS3 protein enhances hepatocellular carcinoma cell invasion by promoting PPM1A ubiquitination and degradation.

Authors:  Yali Zhou; Yan Zhao; Yaoying Gao; Wenjun Hu; Yan Qu; Ning Lou; Ying Zhu; Xiaoping Zhang; Hongmei Yang
Journal:  J Exp Clin Cancer Res       Date:  2017-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.